Prostate
Benign prostatic hyperplasia
Nodular hyperplasia of the prostate’s glands and stroma, driven by dihydrotestosterone, almost universal in old age; enlargement around the urethra obstructs urine outflow.
Causes and risk factors
- Dihydrotestosterone (DHT), made from testosterone by 5α-reductase type 2 in the stroma
- With age, rising oestradiol increases androgen receptors, making the gland more sensitive to DHT
Gross pathology
- An enlarged, nodular prostate, most marked in the lateral lobes; rubbery tissue.
Under the microscope
- Nodules of crowded, enlarged glands with complex infoldings, still lined by two cell layers (columnar and basal) without atypia.
- Corpora amylacea in the glands.
How it develops
- After about 50: Hyperplastic nodules start in the periurethral zone.
- DHT stimulates stromal proliferation and reduces epithelial cell death.
- The enlarging gland compresses the urethra; the bladder empties incompletely.
Complications
- Frequency, difficulty starting and stopping the stream, incomplete emptying
- Obstructive uropathy
- By 80, over 90% of men have some hyperplasia, though only a few have symptoms; it is not a risk factor for carcinoma
Investigations
- Prostate-specific antigen (PSA)
- May be mildly raised; helps weigh the risk of carcinoma.
- Urinalysis and renal function
- Infection, and kidney damage from back-pressure.
- Urine flow rate and post-void residual volume
- A slow stream and urine left in the bladder after voiding.
- Transrectal ultrasound
- The size of the gland.
Drug treatment
- α-Adrenergic blockers: Drugs that block α1 receptors: selective α1-blockers relax prostate and bladder-neck smooth muscle in benign prostatic hyperplasia; the irreversible blocker phenoxybenzamine protects against the catecholamine surges of phaeochromocytoma.
- 5α-Reductase inhibitors: Drugs that block the conversion of testosterone to dihydrotestosterone, shrinking an enlarged prostate over months; they halve the PSA level, which must be taken into account when screening for cancer.
Drugs to avoid or use with care
- Inhaled muscarinic antagonists (LAMA, SAMA) (Use with care): Blocking muscarinic receptors in the bladder can precipitate urinary retention when outflow is already obstructed.
Anatomy involved
Connected topics
Written from
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 12, The Male Genital Tract, pp. 321–322, figs 12-40 to 12-43
Educational reference. Not medical advice, diagnosis or treatment.